Infection and inflammation in schizophrenia and bipolar disorder

Neuroscience Research

Volumn 115, Issue , 2017, Pages 59-63

  Tanaka, Teppei ^a   Matsuda, Taro ^b   Hayes, Lindsay N ^a   Yang, Shuojia ^a   Rodriguez, Katrina ^b   Severance, Emily G ^a   Yolken, Robert H ^a   Sawa, Akira ^a,b   Eaton, William W ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antibody level; Bipolar disorder; Inflammation; Neurocognition; Schizophrenia

Indexed keywords

ANXIOLYTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHLORPROMAZINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MOOD STABILIZER; NEUROLEPTIC AGENT; PENTRAXIN 3; SOLUBLE CD4 ANTIGEN; CD14 ANTIGEN; PROTOZOON ANTIBODY; SERUM AMYLOID P; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ATTENTION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EXECUTIVE FUNCTION; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; INFLAMMATION; INFORMATION PROCESSING; INNATE IMMUNITY; MALE; NONHUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TOXOPLASMA GONDII; TOXOPLASMOSIS; WORKING MEMORY; BIPOLAR DISORDER; BLOOD; CASE CONTROL STUDY; COMPLICATION; HERPES SIMPLEX VIRUS 1; IMMUNOLOGY; INFECTION; MIDDLE AGED; PARASITOLOGY; TOXOPLASMA; VIROLOGY;

ADULT; ANTIBODIES, PROTOZOAN; ANTIBODIES, VIRAL; ANTIGENS, CD14; BIOMARKERS; BIPOLAR DISORDER; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS; FEMALE; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; INFECTION; INFLAMMATION; MALE; MIDDLE AGED; SCHIZOPHRENIA; SERUM AMYLOID P-COMPONENT; TOXOPLASMA;

EID: 85007140443     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2016.11.002     Document Type: Article

References (32)

1. Avramopoulos, D., Pearce, B.D., McGrath, J., Wolyniec, P., Wang, R., Eckart, N., Hatzimanolis, A., Goes, F.S., Nestadt, G., Mulle, J., Coneely, K., Hopkins, M., Ruczinski, I., Yolken, R., Pulver, A.E., Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation. PLoS One, 10, 2015, e0116696.
2. Beattie, E.C., Stellwagen, D., Morishita, W., Bresnahan, J.C., Ha, B.K., Von Zastrow, M., Beattie, M.S., Malenka, R.C., Control of synaptic strength by glial TNFalpha. Science 295 (2002), 2282–2285.
3. Brietzke, E., Stertz, L., Fernandes, B.S., Kauer-Sant'anna, M., Mascarenhas, M., Escosteguy Vargas, A., Chies, J.A., Kapczinski, F., Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 116 (2009), 214–217.
4. Coughlin, J.M., Wang, Y., Ambinder, E.B., Ward, R.E., Minn, I., Vranesic, M., Kim, P.K., Ford, C.N., Higgs, C., Hayes, L.N., Schretlen, D.J., Dannals, R.F., Kassiou, M., Sawa, A., Pomper, M.G., In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Transl. Psychiatry, 6, 2016, e777.
5. Dickerson, F.B., Boronow, J.J., Stallings, C., Origoni, A.E., Cole, S., Krivogorsky, B., Yolken, R.H., Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol. Psychiatry 55 (2004), 588–593.
6. Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Yolken, R., Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J. Affect. Disord. 150 (2013), 456–459.
7. Dickerson, F., Stallings, C., Origoni, A., Katsafanas, E., Schweinfurth, L., Savage, C., Khushalani, S., Yolken, R., Antibodies to Toxoplasma gondii and cognitive functioning in schizophrenia, bipolar disorder, and nonpsychiatric controls. J. Nerv. Ment. Dis. 202 (2014), 589–593.
8. Dickerson, F., Katsafanas, E., Schweinfurth, L.A.B., Savage, C.L.G., Stallings, C., Origoni, A., Khushalani, S., Lillehoj, E., Yolken, R., Immune alterations in acute bipolar depression. Acta Psychiatr. Scand. 132 (2015), 204–210.
9. Eaton, W.W., Kalaydjian, A., Scharfstein, D.O., Mezuk, B., Ding, Y., Prevalence and incidence of depressive disorder: the Baltimore ECA follow-up, 1981–2004. Acta Psychiatr. Scand. 116 (2007), 182–188.
10. Fourgeaud, L., Boulanger, L.M., Role of immune molecules in the establishment and plasticity of glutamatergic synapses. Eur. J. Neurosci. 32 (2010), 207–217.
11. Hamdani, N., Daban-Huard, C., Lajnef, M., Richard, J.-R., Delavest, M., Godin, O., Le Guen, E., Vederine, F.-E., Lépine, J.-P., Jamain, S., Houenou, J., Le Corvoisier, P., Aoki, M., Moins-Teisserenc, H., Charron, D., Krishnamoorthy, R., Yolken, R., Dickerson, F., Tamouza, R., Leboyer, M., Relationship between toxoplasma gondii infection and bipolar disorder in a French sample. J. Affect. Disord. 148 (2013), 444–448.
12. Hayes, L.N., Severance, E.G., Leek, J.T., Gressitt, K.L., Rohleder, C., Coughlin, J.M., Leweke, F.M., Yolken, R.H., Sawa, A., Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr. Bull. 40 (2014), 963–972.
13. Horváth, S., Mirnics, K., Immune system disturbances in schizophrenia. Biol. Psychiatry 75 (2014), 316–323.
14. Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
15. Keefe, R.S.E., Goldberg, T.E., Harvey, P.D., Gold, J.M., Poe, M.P., Coughenour, L., The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 68 (2004), 283–297.
16. Landek-Salgado, M.A., Faust, T.E., Sawa, A., Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol. Psychiatry 21 (2016), 10–28.
17. Leweke, F.M., Gerth, C.W., Koethe, D., Klosterkötter, J., Ruslanova, I., Krivogorsky, B., Torrey, E.F., Yolken, R.H., Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254 (2004), 4–8.
18. Lewitus, G.M., Pribiag, H., Duseja, R., St-Hilaire, M., Stellwagen, D., An adaptive role of TNFα in the regulation of striatal synapses. J. Neurosci. 34 (2014), 6146–6155.
19. Munkholm, K., Braüner, J.V., Kessing, L.V., Vinberg, M., Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J. Psychiatr. Res. 47 (2013), 1119–1133.
20. Owen, M.J., Sawa, A., Mortensen, P.B., Schizophrenia. Lancet 388:10039 (2016), 86–97 PubMed PMID: 26777917.
21. Prasad, K.M., Watson, A.M.M., Dickerson, F.B., Yolken, R.H., Nimgaonkar, V.L., Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. Schizophr. Bull. 38 (2012), 1137–1148.
22. Prasad, K.M., Eack, S.M., Keshavan, M.S., Yolken, R.H., Iyengar, S., Nimgaonkar, V.L., Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial. Schizophr. Bull. 39 (2013), 857–866.
23. Prossin, A.R., Yolken, R.H., Kamali, M., Heitzeg, M.M., Kaplow, J.B., Coryell, W.H., McInnis, M.G., Cytomegalovirus antibody eevation in bipolar disorder: relation to elevated mood states. Neural Plast., 2015, 2015, 939780.
24. Severance, E.G., Gressitt, K.L., Stallings, C.R., Origoni, A.E., Khushalani, S., Leweke, F.M., Dickerson, F.B., Yolken, R.H., Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr. Res. 148 (2013), 130–137.
25. Shirts, B.H., Prasad, K.M., Pogue-Geile, M.F., Dickerson, F., Yolken, R.H., Nimgaonkar, V.L., Antibodies to cytomegalovirus and herpes simplex virus 1 associated with cognitive function in schizophrenia. Schizophr. Res. 106 (2008), 268–274.
26. Stellwagen, D., Malenka, R.C., Synaptic scaling mediated by glial TNF-alpha. Nature 440 (2006), 1054–1059.
27. Stich, O., Andres, T.A., Gross, C.M., Gerber, S.I., Rauer, S., Langosch, J.M., An observational study of inflammation in the central nervous system in patients with bipolar disorder. Bipolar Disord. 17 (2015), 291–302.
28. Storr, C.L., Or, F., Eaton, W.W., Ialongo, N., Genetic research participation in a young adult community sample. J. Community Genet. 5 (2014), 363–375.
29. Sutterland, A.L., Fond, G., Kuin, A., Koeter, M.W.J., Lutter, R., van Gool, T., Yolken, R., Szoke, A., Leboyer, M., de Haan, L., Beyond the association. Toxoplasma gondii in schizophrenia bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr. Scand. 132 (2015), 161–179.
30. Tedla, Y., Shibre, T., Ali, O., Tadele, G., Woldeamanuel, Y., Asrat, D., Aseffa, A., Mihret, W., Abebe, M., Alem, A., Medhin, G., Habte, A., Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiop. Med. J. 49 (2011), 211–220.
31. Toritsuka, M., Kimoto, S., Muraki, K., Landek-Salgado, M.A., Yoshida, A., Yamamoto, N., Horiuchi, Y., Hiyama, H., Tajinda, K., Keni, N., Illingworth, E., Iwamoto, T., Kishimoto, T., Sawa, A., Tanigaki, K., Deficits in microRNA-mediated Cxcr4/Cxcl12 signaling in neurodevelopmental deficits in a 22q11 deletion syndrome mouse model. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 17552–17557.
32. Watkins, C.C., Sawa, A., Pomper, M.G., Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl. Psychiatry, 4, 2014, e350.